Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Astellas Acquires Universal Cells | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Astellas Acquires Universal Cells

For a payment of up to $102.5 million of upfront and milestones

By: Betsy Louda

, Contract Pharma

Astellas Pharma has announced its acquisition of Universal Cells. Astellas will gain Universal Cells’ proprietary Universal Donor Cell technology to create cell therapy products that do not require Human Leukocyte Antigen (HLA) matching, potentially overcoming a huge treatment challenge by reducing the risk of rejection.

 

In October 2017, the Astellas Institute for Regenerative Medicine (AIRM) and Universal Cells entered into an exclusive license agreement to utilize Universal Donor Cell technology in a single indication. Today’s acquisition enables Astellas to fully utilize this proprietary technology in even more therapeutic areas.

 

“We have been very impressed with Universal Cells’ capabilities in cell therapy, including Universal Donor Cell technology, which led us to our initial collaboration and ultimately this acquisition,” commented Yoshihiko Hatanaka, president and chief executive officer, Astellas. “This additional capability will further enable Astellas to develop potential innovative cell therapies for numerous diseases with high unmet medical needs.”

 

“We are thrilled to be able to leverage the full potential of our Universal Donor Cell technology by becoming an intrinsic part of Astellas’ effort to fulfill the promises of Regenerative Medicine to treat diseases,” said Claudia Mitchell, chief executive officer of Universal Cells. “The acquisition represents the recognition of the immense potential of our unique technology and of the outstanding work done by our team at Universal Cells.”

 

Astellas will pay up to $102.5 million of upfront and milestones to acquire 100 percent ownership of Universal Cells depending on achievement of certain specified clinical milestones.

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics